Standard of Care (SOC)

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
43Microscopic polyangiitis1
44Wegener granulomatosis11
49Systemic lupus erythematosus10
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia2
171Wilson disease1

43. Microscopic polyangiitis


Clinical trials : 101 / Drugs : 94 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 87 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

44. Wegener granulomatosis


Clinical trials : 132 / Drugs : 136 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 82 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 768 / Drugs : 558 - (DrugBank : 126) / Drug target genes : 103 - Drug target pathways : 214 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

171. Wilson disease


Clinical trials : 93 / Drugs : 104 - (DrugBank : 18) / Drug target genes : 7 - Drug target pathways : 33 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries